Abstract: The present invention provides cancer treatment preparations of excellent targetability. The sugar chain-modified liposomes of the present invention, which contain an aromatase inhibitor, anti-androgenic agent, lyase inhibitor, GnRH agonist, GnRH antagonist, anti-angiogenic agent, tyrosine kinase inhibitor, serine-threonine kinase inhibitor, antibody having an anticancer activity, ansamitocin, capecitabine, celmoleukin, docetaxel hydrate, gemcitabine hydrochloride, oxaliplatin, prednisolone, tegafur-uracil mixtures, zinostatin stimalamer or arsenic trioxide may be used as cancer treatment preparations having an excellent targetability.

Abstract: A protein and DNA encoding the same are useful as preventives/remedies for diseases such as hypoglycemia, etc. The protein of the present invention is also useful as a reagent for screening a compound that inhibits the binding of the protein of the present invention to IRAP (insulin responsive aminopeptidase) or to GLUT4 (glucose transporter 4). The compound that inhibits the binding of the protein of the present invention to IRAP or GLUT4 is useful as a preventive/remedy for diseases, e.g., hyperglycemia, diabetes mellitus, etc.

Abstract: A protein and DNA encoding the same are useful as preventives/remedies for diseases such as hypoglycemia, etc. The protein of the present invention is also useful as a reagent for screening a compound that inhibits the binding of the protein of the present invention to IRAP (insulin responsive aminopeptidase) or to GLUT4 (glucose transporter 4). The compound that inhibits the binding of the protein of the present invention to IRAP or GLUT4 is useful as a preventive/remedy for diseases, e.g., hyperglycemia, diabetes mellitus, etc.

Abstract: A protein and DNA encoding the same are useful as preventives/remedies for diseases such as hypoglycemia, etc. The protein of the present invention is also useful as a reagent for screening a compound that inhibits the binding of the protein of the present invention to IRAP (insulin responsive aminopeptidase) or to GLUT4 (glucose transporter 4). The compound that inhibits the binding of the protein of the present invention to IRAP or GLUT4 is useful as a preventive/remedy for diseases, e.g., hyperglycemia, diabetes mellitus, etc.

Abstract: It is an object of the present invention to provide an IRAP-binding protein. Specifically, the present invention provides the IRAP-binding protein, pharmaceuticals comprising the protein, a method for screening a compound inhibiting binding of the protein to IRAP, and a compound obtained by the screening method.

Abstract: A protein and DNA encoding the same are useful as preventives/remedies for diseases such as hypoglycemia, etc. The protein of the present invention is also useful as a reagent for screening a compound that inhibits the binding of the protein of the present invention to IRAP (insulin responsive aminopeptidase) or to GLUT4 (glucose transporter 4). The compound that inhibits the binding of the protein of the present invention to IRAP or GLUT4 is useful as a preventive/remedy for diseases, e.g., hyperglycemia, diabetes mellitus, etc.

Abstract: A novel urease having an optimal pH for activity in the acidic region is produced by a microorganism belonging to the genus Lactobacillus or Streptococcus. The urease is superior to the conventional urease in pH stability, temperature stability and alcohol stability.

Abstract: Ethyl carbamate in an alcoholic liquor is decomposed by contacting the alcoholic liquor with a culture broth or processed matter thereof obtained from a microorganism which belongs to the genus Gluconobacter, Flavobacterium, Arthrobacter, Achromobacter, Alcaligenes, Pseudomonas, Klebsiella, Rhodotorula, Rhodosporidium, Trichosporon or Candida, and is capable of decomposing ethyl carbamate. The alcoholic liquor is improved in quality, and has a low ethyl carbamate content.

Abstract: Alcoholic liquors containing carbamide are treated with the urease which has the optimal pH for the activity in an acid region, especially in the region of pH2 to 5. By such treatment, the carbamide can be completely decomposed and removed from the alcoholic liquors in a much smaller amount of urease and in a short time as compared with a conventional treatment according to a urease having the optimal pH in the neutral to alkaline region. This method is more advantageous from the viewpoint of practical use and the quality of the thus obtained alcoholic liquors are superior to that obtained by the conventional treatment.